- Home
- MAIA vs VNRX Comparison
MAIA vs VNRX Comparison
Compare MAIA & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | VNRX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3M | 31.9M |
| IPO Year | 2022 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MAIA | VNRX |
|---|---|---|
| Price | $2.08 | $0.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 553.3K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.53 | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,233,511.00 |
| Revenue This Year | N/A | $60.84 |
| Revenue Next Year | N/A | $404.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $0.87 | $0.17 |
| 52 Week High | $3.19 | $0.94 |
Technical Indicators
Market Signals| Indicator | MAIA | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 38.77 |
| Support Level | $1.61 | N/A |
| Resistance Level | $3.19 | $0.33 |
| Average True Range (ATR) | 0.21 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 51.95 | 28.48 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.